Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments
Sanofi
Summary
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.
Eligibility
- Age range
- 12+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients aged more than or equal to (≥) 12 years at the time of consent. * Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20. * Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) * Signed informed consent for registry participation by the patient or parent/legal representative and assent b…
Locations (43)
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006Birmingham, Alabama
- River Region Dermatology and Laser- Site Number : 8400041Montgomery, Alabama
- San Tan Allergy & Asthma- Site Number : 8400031Gilbert, Arizona
- Kern Research, Inc.- Site Number : 8400047Bakersfield, California
- Center for Dermatology Clinical Research- Site Number : 8400014Fremont, California
- Dermatology Research Associates - Los Angeles- Site Number : 8400020Los Angeles, California